Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Pharmacology

Background:

• Cholesteryl ester transfer protein (CETP) plays a crucial role in cholesterol metabolism and transport.
• Elevated CETP levels are linked to cardiovascular disease (CVD) development.
• CETP facilitates the transfer of cholesteryl esters to apolipoprotein B-containing lipoproteins, influencing atherogenic lipid profiles.

Purpose of the Study:

• To review the role of CETP inhibitors in managing cholesterol levels.
• To discuss the current status of clinical trials involving various CETP inhibitors.
• To analyze the pathophysiology of CETP, its inhibitors' adverse effects, and limitations.

Main Methods:

• Literature review of studies on CETP inhibitors.
• Analysis of clinical trial data for CETP inhibitors (e.g., anacetrapib, torcetrapib, obicetrapib).
• Discussion of the mechanism of action and clinical outcomes related to CETP inhibition.

Main Results:

• CETP inhibition leads to increased high-density lipoprotein (HDL) levels and decreased low-density lipoprotein (LDL) levels.
• Alterations in cholesterol transport by CETP inhibitors contribute to reduced atherosclerosis.
• Clinical trials indicate varying efficacy and safety profiles among different CETP inhibitors.

Conclusions:

• CETP inhibitors represent a therapeutic strategy for reducing 'bad' cholesterol and mitigating CVD risk.
• Further research is needed to optimize the use of CETP inhibitors, considering their adverse effects and limitations.
• Understanding CETP pathophysiology is key to developing safer and more effective lipid-lowering therapies.